<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1186" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1186/" /><meta name="ncbi_pagename" content="Cardiofaciocutaneous Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Cardiofaciocutaneous Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Cardiofaciocutaneous Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/03/03" /><meta name="citation_author" content="Katherine A Rauen" /><meta name="citation_pmid" content="20301365" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1186/" /><meta name="citation_keywords" content="CFC Syndrome" /><meta name="citation_keywords" content="CFC Syndrome" /><meta name="citation_keywords" content="Dual specificity mitogen-activated protein kinase kinase 1" /><meta name="citation_keywords" content="Dual specificity mitogen-activated protein kinase kinase 2" /><meta name="citation_keywords" content="GTPase KRas" /><meta name="citation_keywords" content="Serine/threonine-protein kinase B-raf" /><meta name="citation_keywords" content="BRAF" /><meta name="citation_keywords" content="KRAS" /><meta name="citation_keywords" content="MAP2K1" /><meta name="citation_keywords" content="MAP2K2" /><meta name="citation_keywords" content="Cardiofaciocutaneous Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Cardiofaciocutaneous Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Katherine A Rauen" /><meta name="DC.Date" content="2016/03/03" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1186/" /><meta name="description" content="Cardiofaciocutaneous (CFC) syndrome is characterized by cardiac abnormalities (pulmonic stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, rhythm disturbances), distinctive craniofacial appearance, and cutaneous abnormalities (including xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar hyperkeratosis). The hair is typically sparse, curly, fine or thick, woolly or brittle; eyelashes and eyebrows may be absent or sparse. Nails may be dystrophic or fast growing. Some form of neurologic and/or cognitive delay (ranging from mild to severe) is seen in all affected individuals. Neoplasia, mostly acute lymphoblastic leukemia, has been reported in some individuals." /><meta name="og:title" content="Cardiofaciocutaneous Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Cardiofaciocutaneous (CFC) syndrome is characterized by cardiac abnormalities (pulmonic stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, rhythm disturbances), distinctive craniofacial appearance, and cutaneous abnormalities (including xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar hyperkeratosis). The hair is typically sparse, curly, fine or thick, woolly or brittle; eyelashes and eyebrows may be absent or sparse. Nails may be dystrophic or fast growing. Some form of neurologic and/or cognitive delay (ranging from mild to severe) is seen in all affected individuals. Neoplasia, mostly acute lymphoblastic leukemia, has been reported in some individuals." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1186/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/cfc/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1186/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8ABD22E03F5AA100000000090702E4.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1186_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1186_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ca5a-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/carney/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1186_"><span class="title" itemprop="name">Cardiofaciocutaneous Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: CFC Syndrome</div><p class="contrib-group"><span itemprop="author">Katherine A Rauen</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1186_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1186_ai__"><div class="contrib half_rhythm"><span itemprop="author">Katherine A Rauen</span>, MD, PhD<div class="affiliation small">Professor, Department of Pediatrics<br />Chief, Division of Genomic Medicine<br />University of California, Davis<br />Director, NF/Ras Pathway Clinic<br />UC Davis MIND Institute<br />Sacramento, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.sivadcu@neuar" class="oemail">ude.sivadcu@neuar</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 18, 2007</span>; Last Update: <span itemprop="dateModified">March 3, 2016</span>.</p><p><em>Estimated reading time: 26 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="cfc.Summary" itemprop="description"><h2 id="_cfc_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Cardiofaciocutaneous (CFC) syndrome is characterized by cardiac abnormalities (pulmonic stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, rhythm disturbances), distinctive craniofacial appearance, and cutaneous abnormalities (including xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar hyperkeratosis). The hair is typically sparse, curly, fine or thick, woolly or brittle; eyelashes and eyebrows may be absent or sparse. Nails may be dystrophic or fast growing. Some form of neurologic and/or cognitive delay (ranging from mild to severe) is seen in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Neoplasia, mostly acute lymphoblastic leukemia, has been reported in some individuals.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Diagnosis is based on clinical findings and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. The four genes known to be associated with CFC syndrome are: <i>BRAF</i> (~75%), <i>MAP2K1</i> and <i>MAP2K2</i> (~25%), and <i>KRAS</i> (&#x0003c;2%).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Care by a multidisciplinary team; management of cardiac structural defects, hypertrophic cardiomyopathy, and arrhythmias as in the general population; increased ambient humidity or hydrating lotions for xerosis and pruritus; increased caloric intake and a nasogastric tube or gastrostomy for severe feeding problems; surgical intervention for severe gastroesophageal reflux; routine management of growth hormone deficiency, ocular abnormalities; management of seizures may require polytherapy; occupational therapy, physical therapy, and speech therapy as needed. Consensus medical management guidelines have been published.</p><p><i>Prevention of secondary complications:</i> Antibiotic prophylaxis for subacute bacterial endocarditis primarily for those with valve dysplasias; evaluation for hypertrophic cardiomyopathy or a predisposition to cardiac rhythm disturbances prior to anesthesia.</p><p><i>Surveillance:</i> Periodic echocardiogram (hypertrophic cardiomyopathy), electrocardiogram (rhythm disturbances), neurologic and eye examination, scoliosis check, and assessment of growth and cognitive development.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Cardiofaciocutaneous (CFC) syndrome is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have CFC as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The offspring of an affected individual are at a 50% risk of inheriting a CFC-related pathogenic variant. Prenatal testing for pregnancies at risk is possible if the <i>BRAF</i>, <i>MAP2K1</i>, <i>MAP2K2</i>, or <i>KRAS</i> pathogenic variant has been identified in an affected family member.</p></div></div><div id="cfc.Diagnosis"><h2 id="_cfc_Diagnosis_">Diagnosis</h2><p>Cardiofaciocutaneous (CFC) syndrome is one the RASopathies: a group of syndromes having overlapping clinical features resulting from a common pathogenetic mechanism [<a class="bk_pop" href="#cfc.REF.tidyman.2009a.230">Tidyman &#x00026; Rauen 2009a</a>]. No diagnostic criteria have been established. The diagnosis of CFC syndrome is suspected by clinical findings and confirmed on molecular testing.</p><div id="cfc.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Cardiofaciocutaneous (CFC) syndrome <b>should be suspected</b> in individuals with the following phenotypic features involving the heart, face, and ectodermal structures:</p><ul><li class="half_rhythm"><div><b>Cardiac.</b> Pulmonic stenosis; atrial septal defects; ventricular septal defects; hypertrophic cardiomyopathy; heart valve anomalies (mitral valve dysplasia, tricuspid valve dysplasia, and bicuspid aortic valve); and rhythm disturbances. These defects may be identified at birth or diagnosed later. Hypertrophic cardiomyopathy may be progressive.</div></li><li class="half_rhythm"><div><b>Craniofacial.</b> High forehead, relative macrocephaly, bitemporal narrowing, hypoplasia of the supraorbital ridges, ocular hypertelorism, telecanthus, downslanting palpebral fissures, epicanthal folds, ptosis, short nose with depressed bridge and anteverted nares, ear lobe creases, low-set ears that may be posteriorly rotated, deep philtrum, cupid's bow configuration of the upper lip, high-arched palate, relative micrognathia (<a class="figpopup" href="/books/NBK1186/figure/cfc.F1/?report=objectonly" target="object" rid-figpopup="figcfcF1" rid-ob="figobcfcF1">Figure 1</a>). The face is broader and longer, overall more coarse, than in <a href="/books/n/gene/noonan/">Noonan syndrome</a> (a clinically similar disorder often confused with CFC syndrome), but usually not as coarse as typically seen in <a href="/books/n/gene/costello/">Costello syndrome</a>.</div></li><li class="half_rhythm"><div><b>Ectodermal</b></div><ul><li class="half_rhythm"><div><b>Skin.</b> Xerosis; hyperkeratosis of arms, legs, and face; ichthyosis; keratosis pilaris; ulerythema ophryogenes; eczema; hemangiomas; caf&#x000e9;-au-lait macules; erythema; pigmented moles; palmoplantar hyperkeratosis over pressure zones</div></li><li class="half_rhythm"><div><b>Hair.</b> Sparse, curly, fine or thick, woolly or brittle; sparse to absent, or normal eyelashes and eyebrows</div></li><li class="half_rhythm"><div><b>Nails.</b> Dystrophic with flat broad nails; nails may be fast growing.</div></li></ul></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figcfcF1" co-legend-rid="figlgndcfcF1"><a href="/books/NBK1186/figure/cfc.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figcfcF1" rid-ob="figobcfcF1"><img class="small-thumb" src="/books/NBK1186/bin/cfc-Image001.gif" src-large="/books/NBK1186/bin/cfc-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndcfcF1"><h4 id="cfc.F1"><a href="/books/NBK1186/figure/cfc.F1/?report=objectonly" target="object" rid-ob="figobcfcF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Children with CFC syndrome who have known pathogenic variants in <i>BRAF</i> or <i>MAP2K2</i> A. Three young children with <i>BRAF</i> pathogenic variants: p.Thr470del, in exon 11 (left); p.Ser467Ala, in exon 11 (middle); and p.Gln257Arg, in exon 6 (right). Ages are 2.5, <a href="/books/NBK1186/figure/cfc.F1/?report=objectonly" target="object" rid-ob="figobcfcF1">(more...)</a></p></div></div><p><b>Additional features variably present</b></p><ul><li class="half_rhythm"><div><b>Musculoskeletal.</b> Short neck, pterygium colli, pectus deformity, kyphosis, and/or scoliosis, pes planus</div></li><li class="half_rhythm"><div><b>Lymphatic.</b> Lymphedema, chylothorax</div></li><li class="half_rhythm"><div><b>Ocular.</b> Ocular hypertelorism, strabismus, nystagmus, astigmatism, myopia and/or hyperopia. Optic nerve hypoplasia, cortical blindness, and cataracts have been described. Although most individuals with CFC syndrome have ocular manifestations, some have a normal ophthalmologic examination.</div></li><li class="half_rhythm"><div><b>Feeding/gastrointestinal.</b> Severe feeding problems manifest as gastroesophageal reflux (GER), aspiration, vomiting, and oral aversion. Other GI problems include dysmotility, intestinal malrotation, hernia, and/or constipation. Some individuals have splenomegaly or hepatomegaly. Most children have failure to thrive. Fatty liver and anal stenosis have also been reported.</div></li><li class="half_rhythm"><div><b>Growth delays.</b> Feeding issues contribute to growth delay. Growth may be normal with appropriate birth weight and length; however, weight and length may drop to below the fifth centile during early infancy while head circumference remains within the normal range (resulting in relative macrocephaly).</div></li><li class="half_rhythm"><div><b>Endocrine abnormalities.</b> Growth hormone deficiency in some individuals. Some may have precocious puberty.</div></li><li class="half_rhythm"><div><b>Neurologic.</b> Some aspect of neurologic or neurocognitive findings present in nearly all individuals. Cognitive delay typically ranges from mild to severe, although a few individuals with CFC syndrome have IQs in the normal range. The most common neurologic findings include hypotonia and developmental delay. Other abnormalities can include seizure disorders, abnormal EEG, corticospinal tract findings, hydrocephalus, cortical atrophy versus dilated perivascular spaces, ventriculomegaly, frontal lobe hypoplasia, agenesis of the corpus callosum, abnormal myelination, Chiari malformation, and pachygyria.</div></li><li class="half_rhythm"><div><b>Urogenital.</b> Renal, uterine, and/or cervical anomalies in some individuals</div></li></ul><p>Note: Individuals with CFC syndrome display phenotypic variability and therefore not all have every finding.</p></div><div id="cfc.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of CFC syndrome <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BRAF</i>, <i>MAP2K1</i>, <i>MAP2K2</i>, or <i>KRAS</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1186/table/cfc.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figcfcTmoleculargenetictestingusedin" rid-ob="figobcfcTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p>Consensus guidelines have been developed for a genetic testing strategy for CFC syndrome [<a class="bk_pop" href="#cfc.REF.pierpont.2014.e1149">Pierpont et al 2014</a>]</p><p>Based on current published information, sequencing can be approached stepwise:</p><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> for RASopathies / Noonan spectrum disorders that includes <i>BRAF</i>, <i>MAP2K1</i>, <i>MAP2K2</i>, and <i>KRAS</i> and other genes of interest (see <a href="#cfc.Differential_Diagnosis">Differential Diagnosis</a>) is usually the preferred initial test.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p></dd><dt>2.</dt><dd><p class="no_top_margin">If <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> testing is not available, <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> is recommended, beginning with <i>BRAF</i>, <i>MAP2K1</i>, and <i>MAP2K2</i>, and <i>KRAS</i>; if no pathogenic variants are found follow with sequencing of <i>HRAS</i> (all exons) even though the patient appears to have a clinical diagnosis of CFC syndrome. Individuals who have an <i>HRAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> by definition have <a href="/books/n/gene/costello/">Costello syndrome</a>.</p></dd><dt>3.</dt><dd><p class="no_top_margin">If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in these genes using sequencing analysis, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/duplicaton analysis or array CGH can be considered. Rare deletions in MEK genes (i.e., <i>MAP2K1</i> and <i>MAP2K2</i>) may cause phenotypic features that are reminiscent of CFC syndrome [<a class="bk_pop" href="#cfc.REF.nowaczyk.2014.138">Nowaczyk et al 2014</a>].</p></dd></dl><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> or <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>BRAF</i>, <i>MAP2K1</i>, <i>MAP2K2</i>, and <i>KRAS</i>) fails to confirm a diagnosis in an individual with features of CFC syndrome. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene that results in a similar clinical presentation).</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="cfc.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Cardiofaciocutaneous Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1186/table/cfc.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cfc.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of CFC Attributed to Pathogenic Variants in Gene&#x000a0;<sup>2</sup></th><th id="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>3</sup> Detected by Method</th></tr><tr><th headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRAF</i></td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~75%</td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6,</sup>but single case reported&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MAP2K1</i></td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">~25%</td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MAP2K2</i></td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">~99%</td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup> but several cases have been reported&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KRAS</i></td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2%-3%</td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_cfc.T.molecular_genetic_testing_used_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="cfc.TF.1.1"><p class="no_margin">See <a href="/books/NBK1186/#cfc.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="cfc.TF.1.2"><p class="no_margin"><a class="bk_pop" href="#cfc.REF.rauen.2013.355">Rauen [2013]</a></p></div></dd><dt>3. </dt><dd><div id="cfc.TF.1.3"><p class="no_margin">See <a href="#cfc.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="cfc.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="cfc.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="cfc.TF.1.6"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>7. </dt><dd><div id="cfc.TF.1.7"><p class="no_margin">A single report of a <i>BRAF</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> associated with a CFC-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#cfc.REF.yu.2011.1593">Yu &#x00026; Graf 2011</a>] which was not supported by functional data</p></div></dd><dt>8. </dt><dd><div id="cfc.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#cfc.REF.nowaczyk.2014.138">Nowaczyk et al [2014]</a> reported several individuals with <i>MAP2K2</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> associated with a CFC-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. This was supported by functional data of MAPK pathway dysregulation.</p></div></dd><dt>9. </dt><dd><div id="cfc.TF.1.9"><p class="no_margin">It is unclear at this time whether pathogenic variants in additional, unidentified genes cause CFC syndrome.</p></div></dd></dl></div></div></div></div></div><div id="cfc.Clinical_Characteristics"><h2 id="_cfc_Clinical_Characteristics_">Clinical Characteristics</h2><div id="cfc.Clinical_Description"><h3>Clinical Description</h3><p>Cardiofaciocutaneous (CFC) syndrome affects males and females equally.</p><p><b>Prenatally,</b> polyhydramnios is present in the vast majority of cases. Maternal hyperemesis gravidarum may occur and subjective decrease in fetal movement may be observed. Newborns may be premature and large for gestational age, although the majority are appropriate for gestational age.</p><p><b>In the neonate,</b> distinctive craniofacial features are present. Chylothorax and lymphedema have been reported at birth. Cardiac abnormalities, when present, typically present at birth, although hypertrophic cardiomyopathy and rhythm disturbances may present later in life. Feeding difficulties may be present.</p><p><b>In infancy,</b> severe feeding difficulties are common, resulting in failure to thrive. Many children require nasogastric or gastrostomy feeding, while some undergo a Nissen fundoplication procedure for severe gastroesophageal reflux. Constipation is typically reported and continues to be an issue throughout childhood and adolescence.</p><p>All children have some form of neurologic abnormalities, neurocognitive delay, or learning issues. Overall, developmental delay typically ranges from mild to profoundly severe. A few individuals have IQs in the normal range. Children have speech delays and the vast majority have hypotonia, causing motor delays.</p><p><b>Childhood and adolescence.</b> At present, no longitudinal or natural history studies have been done for CFC syndrome. However, CFC syndrome does have an evolving <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><ul><li class="half_rhythm"><div><b>Feeding issues.</b> Later in childhood, feeding difficulties and hypotonia improve. Oral feedings are achieved usually in early childhood.</div></li><li class="half_rhythm"><div><b>Growth failure</b> affects most individuals with CFC syndrome. Although the vast majority of children may not be tested, some have growth hormone deficiency.</div></li><li class="half_rhythm"><div><b>Neurodevelopmental delay</b> may be less obvious in mildly or moderately <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, but speech delays and difficulty walking become apparent in those who are more severely affected. Some young adults participate in assisted living programs.</div></li><li class="half_rhythm"><div><b>Seizures.</b> Nearly 50% of individuals with CFC and a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of its associated genes have a seizure disorder. Most seizures begin in infancy or early childhood [<a class="bk_pop" href="#cfc.REF.yoon.2007.894">Yoon et al 2007</a>]; however, a seizure disorder may develop later in childhood as well.</div></li><li class="half_rhythm"><div><b>Otolaryngologic problems.</b> Many children have recurrent otitis media and are found to have narrow external auditory canals.</div></li><li class="half_rhythm"><div><b>Ocular abnormalities</b> including strabismus, nystagmus, optic nerve hypoplasia, astigmatism, myopia, and/or hyperopia are present in most individuals and may result in decreased vision and acuity.</div></li><li class="half_rhythm"><div><b>Cardiac issues</b>
<b>abnormalities</b> occur in approximately 75%-80% of indiividuals and include hypertrophic cardiomyopathy, structural anomalies, and (more rarely) rhythm disturbances.</div></li><li class="half_rhythm"><div><b>Renal/ urogenital anomalies.</b> Anomalies can occur in up to 33% of individuals, with cryptorchidism in males being the most common. Renal cysts and stones as well as hydronephrosis and hydroureter can also occur.</div></li><li class="half_rhythm"><div><b>Bleeding diathesis.</b> von Willebrand disorder has been reported.</div></li><li class="half_rhythm"><div><b>Dermatologic.</b> With age, the dryness of the skin and the follicular hyperkeratosis tend to improve, allowing the hair to grow on the face and scalp [<a class="bk_pop" href="#cfc.REF.roberts.2006.833">Roberts et al 2006</a>]; however, palmoplantar hyperkeratosis and lymphedema may become more severe. Nevi, when present, increase in number over time [<a class="bk_pop" href="#cfc.REF.siegel.2011.521">Siegel et al 2011</a>]. Individuals with CFC syndrome have been known to develop severe skin infections.</div></li><li class="half_rhythm"><div><b>Musculoskeletal.</b> The vast majority of individuals have musculoskeletal findings including hypotonia with a paucity of muscle mass and lax joints. Orthopedic issues include pectus deformity, scoliosis, kyphosis, and/or gait disturbances.</div></li><li class="half_rhythm"><div><b>Appearance.</b> By late adolescence to early adulthood, the craniofacial appearance becomes less like that seen in Noonan syndrome.</div></li><li class="half_rhythm"><div><b>Neoplasias</b> (e.g., benign papillomas or malignancies observed in the other RASopathies including <a href="/books/n/gene/costello/">Costello syndrome</a>, <a href="/books/n/gene/noonan/">Noonan syndrome</a>, or <a href="/books/n/gene/nf1/">neurofibromatosis type 1</a>) have not been reported in CFC syndrome. However, acute lymphoblastic leukemia (ALL) has now been reported in a few individuals [<a class="bk_pop" href="#cfc.REF.niihori.2006.294">Niihori et al 2006</a>, <a class="bk_pop" href="#cfc.REF.makita.2007.287">Makita et al 2007</a>, <a class="bk_pop" href="#cfc.REF.rauen.2010.807">Rauen et al 2010</a>], hepatoblastoma in an immunocompromised individual [<a class="bk_pop" href="#cfc.REF.alrahawan.2007.1481">Al-Rahawan et al 2007</a>], non-Hodgkin lymphoma [<a class="bk_pop" href="#cfc.REF.ohtake.2011.e342">Ohtake et al 2011</a>], and large B-cell lymphoma [<a class="bk_pop" href="#cfc.REF.rauen.2010.807">Rauen et al 2010</a>].</div></li></ul></div><div id="cfc.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Further evaluation of more individuals with CFC syndrome is necessary to clarify <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a>, thereby permitting more accurate prognoses.</p><p>Ongoing correlations include the following:</p><ul><li class="half_rhythm"><div>Pulmonic stenosis is present in 50% of CFC individuals with a <i>BRAF</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> as opposed to 37% with a MEK pathogenic variant [<a class="bk_pop" href="#cfc.REF.allanson.2011.129">Allanson et al 2011</a>].</div></li><li class="half_rhythm"><div>Individuals with the <i>BRAF</i>
<a class="figpopup" href="/books/NBK1186/table/cfc.T.selected_braf_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figcfcTselectedbrafpathogenicvariants" rid-ob="figobcfcTselectedbrafpathogenicvariants">p.Gln257Arg</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the most common CFC pathogenic variant, have many phenotypic features in common, including characteristic facies, cardiac defects, short stature, failure to thrive, abnormal brain imaging, musculoskeletal and ocular abnormalities, and relatively mild developmental delay [<a class="bk_pop" href="#cfc.REF.niihori.2006.294">Niihori et al 2006</a>, <a class="bk_pop" href="#cfc.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana et al 2006</a>].</div></li><li class="half_rhythm"><div>Individuals with a <i>MAP2K1</i> or <i>MAP2K2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are more likely to have keratosis pilaris and progressive nevi formation than those with a <i>BRAF</i> pathogenic variant [<a class="bk_pop" href="#cfc.REF.siegel.2011.521">Siegel et al 2011</a>].</div></li></ul></div><div id="cfc.Penetrance"><h3>Penetrance</h3><p>Penetrance is complete in CFC syndrome.</p></div><div id="cfc.Nomenclature"><h3>Nomenclature</h3><p><a class="bk_pop" href="#cfc.REF.blumberg.1979">Blumberg et al [1979]</a> at the March of Dimes Birth Defects Conference reported three individuals with intellectual disability who also had characteristic craniofacial dysmorphology, ectodermal anomalies, and cardiac defects. These three persons, along with five others, were subsequently reported by <a class="bk_pop" href="#cfc.REF.reynolds.1986.413">Reynolds et al [1986]</a>, who designated this new disorder cardiofaciocutaneous syndrome. Also <a class="bk_pop" href="#cfc.REF.baraitser.1986.161">Baraitser &#x00026; Patton [1986]</a> reported on a Noonan syndrome-like short stature syndrome with ectodermal anomalies that was presumed to be the same entity.</p></div><div id="cfc.Prevalence"><h3>Prevalence</h3><p>More than 100 individuals with CFC syndrome have been reported in the literature. The total number of individuals worldwide with CFC syndrome is estimated to be several hundred, yet this may be an underestimation because of underdiagnosis of mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Overall prevalence is not known; prevalence in Japan is estimated at one in 810,000 [<a class="bk_pop" href="#cfc.REF.abe.2012.1083">Abe et al 2012</a>].</p></div></div><div id="cfc.Genetically_Related_Allelic_Disorder"><h2 id="_cfc_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><div id="cfc.BRAF"><h3><i>BRAF</i></h3><p><a href="/books/n/gene/leopard/"><b>Noonan syndrome with multiple lentigines</b></a>
<b>(NSML).</b>
<i>BRAF</i> pathogenic variants have been reported in a few individuals who were given a clinical diagnosis of NSML (previously referred to as LEOPARD syndrome).</p><p><a href="/books/n/gene/noonan/"><b>Noonan syndrome</b></a><b>.</b>
<i>BRAF</i> pathogenic variants have been reported in a few individuals who were given a clinical diagnosis of Noonan syndrome.</p><p>Note: While individuals with a clinical diagnosis of either NSML or Noonan syndrome have been reported in the medical literature to be associated with pathogenic variants in <i>BRAF</i> [<a class="bk_pop" href="#cfc.REF.sarkozy.2009.695">Sarkozy et al 2009</a>], the author feels strongly that a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BRAF</i> molecularly defines CFC syndrome.</p></div><div id="cfc.KRAS"><h3><i>KRAS</i></h3><p><a href="/books/n/gene/noonan/"><b>Noonan syndrome</b></a><b>.</b>
<i>KRAS</i> pathogenic variants have been identified in fewer than 5% of individuals with the clinical diagnosis of Noonan syndrome [<a class="bk_pop" href="#cfc.REF.carta.2006.129">Carta et al 2006</a>, <a class="bk_pop" href="#cfc.REF.schubbert.2006.331">Schubbert et al 2006</a>, <a class="bk_pop" href="#cfc.REF.zenker.2007.131">Zenker et al 2007</a>].</p></div></div><div id="cfc.Differential_Diagnosis"><h2 id="_cfc_Differential_Diagnosis_">Differential Diagnosis</h2><p>Multigene panels may include testing for a number of the genes associated with disorders discussed in this section.</p><p><a href="/books/n/gene/costello/"><b>Costello syndrome</b></a> is characterized by failure to thrive in infancy as a result of severe postnatal feeding difficulties; short stature; developmental delay or intellectual disability; coarse facial features (full lips, large mouth, full nasal tip); curly or sparse, fine hair; loose, soft skin with deep palmar and plantar creases; papillomata of the face and perianal region; diffuse hypotonia and joint laxity with ulnar deviation of the wrists and fingers; tight Achilles tendons; and cardiac involvement including: cardiac hypertrophy (usually typical hypertrophic cardiomyopathy [HCM]), <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defect (usually valvar pulmonic stenosis), and arrhythmia (usually supraventricular tachycardia, especially chaotic atrial rhythm/multifocal atrial tachycardia or ectopic atrial tachycardia). Relative or absolute macrocephaly is typical, and postnatal cerebellar overgrowth can result in the development of a Chiari I malformation with associated anomalies including hydrocephalus or syringomyelia. Individuals with Costello syndrome are at an approximately 15% lifetime risk for malignant tumors including rhabdomyosarcoma and neuroblastoma in young children and transitional cell carcinoma of the bladder in adolescents and young adults.</p><p>Germline pathogenic variants in <i>HRAS</i> are causative [<a class="bk_pop" href="#cfc.REF.aoki.2005.1038">Aoki et al 2005</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> as demonstrated by <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#cfc.REF.solchurch.2009.315">Sol-Church et al 2009</a>].</p><p>Individuals identified with <i>HRAS</i> pathogenic variants by definition have the diagnosis of Costello syndrome. <i>BRAF</i> pathogenic variants have been identified in individuals with a Costello syndrome-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> who did not have an <i>HRAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#cfc.REF.rauen.2006.1681">Rauen 2006</a>]. However, with closer clinical examination, the clinical diagnosis was consistent with CFC syndrome. Costello syndrome and cardiofaciocutaneous (CFC) syndrome have many overlapping phenotypic features, underscoring the difficulty in making a clinical diagnosis based on phenotypic features alone. Individuals with <i>BRAF</i> pathogenic variants have the diagnosis of CFC syndrome, even if they have features that may be present in Costello syndrome or have phenotypic overlap with Noonan syndrome (see following).</p><p><a href="/books/n/gene/noonan/"><b>Noonan syndrome</b></a> is characterized by short stature, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, characteristic facies, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one third of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have mild intellectual disability.</p><p>Pathogenic variants in <i>PTPN11</i> have been identified in approximately 50% of individuals with clinically diagnosed Noonan syndrome [<a class="bk_pop" href="#cfc.REF.tartaglia.2001.465">Tartaglia et al 2001</a>]. <i>SOS1</i> pathogenic variants have been identified in approximately 13% of individuals with Noonan syndrome [<a class="bk_pop" href="#cfc.REF.roberts.2006.833">Roberts et al 2006</a>, <a class="bk_pop" href="#cfc.REF.tartaglia.2007.75">Tartaglia et al 2007</a>]. <i>KRAS</i> pathogenic variants have been reported in fewer than 5% [<a class="bk_pop" href="#cfc.REF.schubbert.2006.331">Schubbert et al 2006</a>]. <i>RAF1</i> pathogenic variants have been reported in 3% to 17%. Other genes in which pathogenic variants have been reported to cause Noonan syndrome in fewer than 1% of cases include <i>NRAS</i> [<a class="bk_pop" href="#cfc.REF.cirstea.2010.27">Cirstea et al 2010</a>], <i>BRAF</i>, and <i>MAP2K1</i>.</p><p>Craniofacial findings in CFC syndrome are reminiscent of those described in Noonan syndrome (macrocephaly, broad forehead, bitemporal narrowing, hypoplasia of the supraorbital ridges, downslanting palpebral fissures with ptosis, short nose with depressed nasal bridge and anteverted nares, low-set ears with prominent helices which may be posteriorly rotated, and high-arched palate), underscoring the importance of molecular testing to establish the correct diagnosis.</p><p>Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; however, many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals most likely have <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants.</p></div><div id="cfc.Management"><h2 id="_cfc_Management_">Management</h2><div id="cfc.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with or suspected to have cardiofaciocutaneous (CFC) syndrome, the following evaluations are recommended. Evaluations are based on published consensus guidelines for workup at initial diagnosis or as ongoing medical management throughout an individual's life span [<a class="bk_pop" href="#cfc.REF.pierpont.2014.e1149">Pierpont et al 2014</a>]</p><ul><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li><li class="half_rhythm"><div>Complete physical examination including measurement of growth parameters</div></li><li class="half_rhythm"><div>Nutrition and feeding evaluation; consideration of swallow study</div></li><li class="half_rhythm"><div>Endocrine evaluation</div></li><li class="half_rhythm"><div>Psychomotor developmental evaluation</div></li><li class="half_rhythm"><div>Neurologic evaluation</div></li><li class="half_rhythm"><div>MRI of the brain to detect any structural changes</div></li><li class="half_rhythm"><div>Electroencephalogram if seizures are suspected</div></li><li class="half_rhythm"><div>Audiologic examination</div></li><li class="half_rhythm"><div>Ophthalmologic examination</div></li><li class="half_rhythm"><div>Cardiac evaluation including echocardiogram and electrocardiogram</div></li><li class="half_rhythm"><div>Full abdominal ultrasound examination to evaluate for renal and urogenital anomalies</div></li><li class="half_rhythm"><div>Obtain history for possible bleeding diathesis</div></li><li class="half_rhythm"><div>Dermatologic evaluation</div></li></ul></div><div id="cfc.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Consensus guidelines for workup at initial diagnosis or as ongoing medical management throughout an individual's life span have been published [<a class="bk_pop" href="#cfc.REF.pierpont.2014.e1149">Pierpont et al 2014</a>].</p><p>CFC syndrome affects many organ systems and, therefore, the vast majority of individuals require ongoing care by a multidisciplinary team of healthcare providers. At present, phenotypic features caused by <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>BRAF</i>, <i>MAP2K1</i>, <i>MAP2K2</i>, or <i>KRAS</i> are treated as in the general population.</p><ul><li class="half_rhythm"><div>Severe feeding issues during the first years of life require management by a pediatric gastroenterologist. Many children with CFC syndrome require nasogastric or gastrostomy tube feeding because of failure to thrive. Increasing caloric intake may be of benefit. Children with severe gastroesophageal reflux may require a Nissen fundoplication. Constipation affects the majority of individuals; increased fiber in the diet, under the direction of a pediatrician, may be beneficial.</div></li><li class="half_rhythm"><div>Some individuals are growth hormone- and or thyroid hormone-deficient and may benefit from management by an endocrinologist. Individuals with a diagnosis of hypertrophic cardiomyopathy must be monitored closely while on growth hormone therapy.</div></li><li class="half_rhythm"><div>Enrollment in early-intervention therapies to promote motor and intellectual development (e.g., occupational therapy, physical therapy, or speech therapy) is highly recommended.</div></li><li class="half_rhythm"><div>Seizures are treated as in the general population. However, seizures may be refractory to single-agent therapy and may require polytherapy.</div></li><li class="half_rhythm"><div>Recurrent otitis media may require placement of PE tubes.</div></li><li class="half_rhythm"><div>Ocular abnormalities such as myopia or hyperopia are corrected with lenses as in the general population.</div></li><li class="half_rhythm"><div>Cardiovascular management is dictated by the abnormality, with treatment similar to that in the general population: structural defects are managed surgically as needed; hypertrophic cardiomyopathy is followed by serial echocardiograms, and cardiac arrhythmias are medically managed in an aggressive manner.</div></li><li class="half_rhythm"><div>Xerosis and pruritus may be relieved by increasing the ambient humidity or using hydrating lotions. Hyperkeratoses are treated as in the general population.</div></li><li class="half_rhythm"><div>Signs and symptoms of skin infection, especially in the presence of lymphedema, warrant thorough and immediate evaluation by a physician for the consideration of antibiotic treatment.</div></li><li class="half_rhythm"><div>Musculoskeletal abnormalities, such as scoliosis or pectus deformity, are managed as in the general population.</div></li></ul><p>Note: Specialized NF/Ras pathway genetics clinics are available in the US and United Kingdom.</p></div><div id="cfc.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p><b>Cardiac.</b> Certain <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defects (notably valve dysplasias) require antibiotic prophylaxis for subacute bacterial endocarditis (SBE).</p><p><b>Anesthesia.</b> Individuals with CFC syndrome may have an unrecognized hypertrophic cardiomyopathy, tracheomalacia, or a predisposition to cardiac rhythm disturbances and should be evaluated for these issues prior to anesthetic administration.</p></div><div id="cfc.Surveillance"><h3>Surveillance</h3><p>If anomalies are identified in any organ system, lifelong periodic follow up is warranted. Consensus guidelines for surveillance in CFC syndrome have been established [<a class="bk_pop" href="#cfc.REF.pierpont.2014.e1149">Pierpont et al 2014</a>].</p><ul><li class="half_rhythm"><div><b>Gastrointestinal.</b> Monitor for signs and symptoms of gastrointestinal reflux, constipation, and generalized dysmotility.</div></li><li class="half_rhythm"><div><b>Endocrine.</b> Monitor growth parameters to identify evidence of growth failure that may be associated with growth hormone deficiency. Monitor for signs of precocious puberty.</div></li><li class="half_rhythm"><div><b>Cognitive development.</b> Assess periodically to be certain that school programs or other supports are addressing learning needs.</div></li><li class="half_rhythm"><div><b>Neurologic.</b> Monitor neurologic signs and symptoms with period neurologic evaluations and MRI if indicated. Chiari malformation and later onset of seizures have been observed.</div></li><li class="half_rhythm"><div><b>Audiologic</b>. Annual evaluation of hearing is recommended.</div></li><li class="half_rhythm"><div><b>Ophthalmologic.</b> Periodic evaluation by an ophthalmologist to monitor for ocular issues (such as myopia, hyperopia, cataracts) is recommended.</div></li><li class="half_rhythm"><div><b>Cardiac.</b> If the initial cardiac evaluation is normal, periodic follow-up evaluations including an echocardiogram and an electrocardiogram are necessary as hypertrophic cardiomyopathy and rhythm disturbances may develop later in life.</div></li><li class="half_rhythm"><div><b>Dermatologic.</b> As <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals age, formation of nevi may be progressive. At present, the natural history of the nevi is unknown. Periodic and routine dermatologic evaluation of nevi may be warranted to monitor for malignant change, although <b>no</b> individuals with CFC syndrome have been reported to have a malignant change.</div></li><li class="half_rhythm"><div><b>Musculoskeletal.</b> Periodic evaluation for scoliosis during young childhood is recommended.</div></li><li class="half_rhythm"><div><b>Malignancy.</b> No screening protocol exists at present, as it is unclear if individuals with CFC syndrome are at an increased risk for malignancies.</div></li></ul></div><div id="cfc.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Over-exposure to heat.</b> Individuals with CFC syndrome report heat intolerance.</p></div><div id="cfc.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#cfc.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="cfc.Pregnancy_Management"><h3>Pregnancy Management</h3><p>A pregnant female suspected of having CFC syndrome warrants obstetric care from a trained maternal-fetal-medicine physician due to possible polyhydramnios, cardiac issues, and/or hypertension.</p></div><div id="cfc.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Because the Ras/MAPK pathway has been studied intensively in the context of cancer, numerous therapeutics that specifically target this pathway are in development.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="cfc.Genetic_Counseling"><h2 id="_cfc_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="cfc.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Cardiofaciocutaneous (CFC) syndrome is transmitted in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner [<a class="bk_pop" href="#cfc.REF.rauen.2010.807">Rauen et al 2010</a>]. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date have had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="cfc.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The vast majority of individuals with CFC syndrome reported to date have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>BRAF</i>, <i>MAP2K1</i>, <i>MAP2K2</i>, or <i>KRAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>In rare cases, individuals diagnosed with CFC have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Autosomal dominant inheritance of <i>MAP2K2</i> and <i>KRAS</i>-related CFC has been reported in several families [<a class="bk_pop" href="#cfc.REF.rauen.2010.807">Rauen et al 2010</a>, <a class="bk_pop" href="#cfc.REF.stark.2012.590">Stark et al 2012</a>].</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the pathogenic variant identified in the proband or, if a pathogenic variant has not been identified in the proband, a detailed medical history as well as physical examination of the parents to identify phenotypic features of CFC.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent (although no instances of germline mosaicism have been reported, it remains a possibility).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>As most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date have had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>BRAF</i>, <i>MAP2K1</i>, <i>MAP2K2</i>, or <i>KRAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, risk to sibs is presumed to be low. However, because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent, the risk may be greater than in the general population.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with CFC syndrome has a 50% chance of inheriting the <i>BRAF</i>, <i>MAP2K1</i>, <i>MAP2K2</i>, or <i>KRAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members may be at risk.</p></div><div id="cfc.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to couples if one of the two has CFC syndrome or if they have had an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child.</div></li></ul><p><b>The importance of determining the genetic etiology using <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</b>
<a href="/books/n/gene/noonan/">Noonan syndrome</a> and CFC syndrome have phenotypic overlap; thus, determining the genetic etiology by molecular testing is important to establish the correct diagnosis in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and allow for accurate <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="cfc.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>BRAF</i>, <i>KRAS</i>, <i>MAP2K2</i>, <i>or MAP2K1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for CFC are possible.</p></div></div><div id="cfc.Resources"><h2 id="_cfc_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>CFC International</b></div><div>183 Brown Road</div><div>Vestal NY 13850</div><div><b>Phone:</b> 607-772-9666</div><div><b>Fax:</b> 607-748-0409</div><div><b>Email:</b> info@cfcsyndrome.org</div><div><a href="http://www.cfcsyndrome.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cfcsyndrome.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Cardiofaciocutaneous%20syndrome&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cardiofaciocutaneous syndrome</a></div></li><li class="half_rhythm"><div><b>RASopathiesNet</b></div><div>244 Taos Road</div><div>Atlandena CA 91001</div><div><b>Phone:</b> 626-676-7694</div><div><b>Email:</b> lisa@rasopathies.org</div><div><a href="http://rasopathiesnet.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rasopathiesnet.org</a></div></li></ul></div><div id="cfc.Molecular_Genetics"><h2 id="_cfc_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="cfc.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Cardiofaciocutaneous Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1186/table/cfc.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cfc.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_cfc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_cfc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_cfc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_cfc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_cfc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_cfc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_cfc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/673" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BRAF</i></a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=673" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q34</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P15056" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Serine/threonine-protein kinase B-raf</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/BRAF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRAF database</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRAF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRAF</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRAF[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRAF</a></td></tr><tr><td headers="hd_b_cfc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3845" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KRAS</i></a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3845" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12p12<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P01116" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GTPase KRas</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/KRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRAS database</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRAS</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KRAS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRAS</a></td></tr><tr><td headers="hd_b_cfc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5604" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MAP2K1</i></a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5604" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q22<wbr style="display:inline-block"></wbr>​.31</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q02750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dual specificity mitogen-activated protein kinase kinase 1</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/MAP2K1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K1 @ LOVD</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MAP2K1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K1</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MAP2K1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K1</a></td></tr><tr><td headers="hd_b_cfc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5605" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MAP2K2</i></a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5605" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P36507" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dual specificity mitogen-activated protein kinase kinase 2</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/MAP2K2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K2 database</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MAP2K2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K2</a></td><td headers="hd_b_cfc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MAP2K2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="cfc.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="cfc.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Cardiofaciocutaneous Syndrome (<a href="/omim/115150,164757,176872,190070,601263,615278,615279,615280" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1186/table/cfc.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cfc.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/115150" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">115150</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/164757" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">164757</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1; BRAF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176872" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176872</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1; MAP2K1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/190070" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">190070</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KRAS PROTOONCOGENE, GTPase; KRAS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601263" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601263</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2; MAP2K2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/615278" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615278</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CARDIOFACIOCUTANEOUS SYNDROME 2; CFC2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/615279" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615279</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CARDIOFACIOCUTANEOUS SYNDROME 3; CFC3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/615280" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615280</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CARDIOFACIOCUTANEOUS SYNDROME 4; CFC4</td></tr></tbody></table></div></div><div id="cfc.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The four genes currently known to be associated with cardiofaciocutaneous (CFC) syndrome are in the Ras/mitogen-activated protein kinase (MAPK) signaling cascade. The MAPK signaling cascade of dual-specificity kinases [<a class="bk_pop" href="#cfc.REF.rauen.2011.136">Rauen et al 2011</a>] (see <a href="/pmc/articles/PMC4145816/figure/F1/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Figure 1</a>) is highly conserved among eukaryotic organisms and is critically involved in cell proliferation, differentiation, motility, apoptosis, and senescence. The Ras/Raf/MEK/ERK signal transduction pathway is activated by extracellular stimuli. Activated Ras recruits Raf, the first kinase of the cascade, to the cell membrane. Activated Raf phosphorylates MEK1 (encoded by <i>MAP2K1</i>) and/or MEK2 (encoded by <i>MAP2K2</i>), which then phosphorylates ERK1 and/or ERK2 (aka MAPK). <a href="/books/n/gene/noonan/">Noonan syndrome</a> has been associated with pathogenic variants in <i>PTPN11</i> (protein product SHP2), <i>SOS1</i>, <i>SOS2</i>, <i>RAF1</i> (protein product CRAF), <i>NRAS</i>, <i>RIT1</i>, <i>LZTR1</i>, <i>RRAS</i> and <i>KRAS</i>. Pathogenic variants in <i>HRAS</i> are causative for <a href="/books/n/gene/costello/">Costello syndrome</a>. CFC syndrome is associated with pathogenic variants in <i>BRAF</i>, <i>MAP2K1</i>, and <i>MAP2K2</i>. Because <i>KRAS</i> pathogenic variants were identified in individuals clinically diagnosed with CFC syndrome or with <a href="/books/n/gene/noonan/">Noonan syndrome</a> [<a class="bk_pop" href="#cfc.REF.niihori.2006.294">Niihori et al 2006</a>, <a class="bk_pop" href="#cfc.REF.schubbert.2006.331">Schubbert et al 2006</a>], the role of its protein product GTPase KRas (KRAS) in CFC syndrome has yet to be clarified.</p><div id="cfc.BRAF_1"><h4><i>BRAF</i></h4><p><b>Gene structure.</b>
<i>BRAF</i> encodes BRAF, a member of the Raf family, which also includes CRAF and ARAF encoded by the <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>ARAF</i>. <i>BRAF</i> spans approximately 190 kb and contains 18 exons. For a detailed summary of gene and protein information, see <a href="/books/NBK1186/#cfc.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The spectrum of <i>BRAF</i> pathogenic variants in individuals with CFC syndrome is similar to the spectrum of somatic pathogenic variants observed in cancer. However, pathogenic variants associated with CFC syndrome are more widely distributed within the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and many are novel, never having been identified in cancer. Pathogenic variants are heterogeneous and cluster mainly in two regions, the cysteine-rich <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of the CR1 and the protein kinase domain. Nearly all pathogenic variants published to date have been <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants. However, rare <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions have been identified in <i>BRAF</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 [<a class="bk_pop" href="#cfc.REF.yoon.2007.894">Yoon et al 2007</a>].</p><div id="cfc.T.selected_braf_pathogenic_variants" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>BRAF</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1186/table/cfc.T.selected_braf_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cfc.T.selected_braf_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.770A&#x0003e;G</td><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln257Arg&#x000a0;<sup>1</sup></td><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_3" rowspan="8" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_004333.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004333<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_004324.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004324<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1399T&#x0003e;G</td><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser467Ala&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1408_1410del</td><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr470del&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1455G&#x0003e;C</td><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu485Phe&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1600G&#x0003e;C</td><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly534Arg&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1787G&#x0003e;T</td><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly596Val</td></tr><tr><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1799T&#x0003e;A</td><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val600Glu&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1799T&#x0003e;G</td><td headers="hd_h_cfc.T.selected_braf_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val600Gly</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="cfc.TF.2.1"><p class="no_margin">See <a class="figpopup" href="/books/NBK1186/figure/cfc.F1/?report=objectonly" target="object" rid-figpopup="figcfcF1" rid-ob="figobcfcF1">Figure 1</a>.</p></div></dd><dt>2. </dt><dd><div id="cfc.TF.2.2"><p class="no_margin">Associated with Costello syndrome; see <a class="figpopup" href="/books/NBK1186/figure/cfc.F1/?report=objectonly" target="object" rid-figpopup="figcfcF1" rid-ob="figobcfcF1">Figure 1</a>.</p></div></dd><dt>3. </dt><dd><div id="cfc.TF.2.3"><p class="no_margin">p.Val600Glu is a <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a> found in some solid tumors (see <a href="#cfc.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</a>).</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The protein product of <i>BRAF</i> is BRAF, a serine/threonine protein kinase that is one of the many direct downstream effectors of Ras. The Raf/MEK/ERK module of kinases is critically involved in cell proliferation, differentiation, motility, apoptosis, and senescence. BRAF has only two known downstream effectors, mitogen-activated protein kinase 1 and 2 (also known as MEK1 and MEK2). There are three conserved regions in BRAF. Conserved region 1 (CR1) contains the Ras binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and the cysteine-rich domain, both of which are required for recruitment of BRAF to the cell membrane. CR2 is the smallest of the conserved regions and CR3 is the kinase domain containing the glycine-rich loop (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11) and the activation segment (exon 15) of the catalytic domain.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The type of <i>BRAF</i> pathogenic variants found in CFC syndrome is similar to the types of somatic pathogenic variants found in cancers with high kinase and kinase-impaired activities [<a class="bk_pop" href="#cfc.REF.niihori.2006.294">Niihori et al 2006</a>, <a class="bk_pop" href="#cfc.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana et al 2006</a>]. In addition, CFC syndrome BRAF mutated proteins activate downstream effectors in vitro, as determined by measuring phosphorylated species of MEK and ERK. Both cancer and CFC syndrome-associated BRAF mutated proteins with elevated kinase activity induce higher levels of MEK and ERK phosphorylation compared with <a class="def" href="/books/n/gene/glossary/def-item/wild-type/">wild-type</a> BRAF, whereas kinase-impaired BRAF mutated proteins are impaired in their ability to induce phosphorylation of MEK and ERK [<a class="bk_pop" href="#cfc.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana et al 2006</a>]. The most common <i>BRAF</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in cancer, p.Val600Glu, has not been identified in CFC syndrome. Presumably, such a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variant would be incompatible with life. However, a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> p.Val600Gly pathogenic variant has recently been reported in CFC [<a class="bk_pop" href="#cfc.REF.champion.2011.468">Champion et al 2011</a>] and, like the <i>BRAF</i> p.Val600Glu pathogenic variant, has also been reported in cancer.</p><p><b>Cancer and benign tumors &#x02013; solid tumors.</b> Somatic pathogenic variants in <i>BRAF</i> have been reported in approximately 8% of tumors with <i>BRAF</i> most frequently mutated in melanoma, thyroid, colorectal, and ovarian. The vast majority of <i>BRAF</i> pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> substitutions found in (but not limited to) <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 (the glycine-rich loop) and exon 15 (the activation segment) in the BRAF kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> [<a class="bk_pop" href="#cfc.REF.wellbrock.2004.875">Wellbrock et al 2004</a>]. One <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, p.Val600Glu, which results in increased kinase activity, accounts for more than 90% of <i>BRAF</i> pathogenic variants identified in human cancer. Somatic <i>BRAF</i> p.Val600Glu pathogenic variants are also found in benign nevi and premalignant colon polyps. The common <a class="figpopup" href="/books/NBK1186/table/cfc.T.selected_braf_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figcfcTselectedbrafpathogenicvariants" rid-ob="figobcfcTselectedbrafpathogenicvariants">p.Val600Glu</a> cancer pathogenic variant has never been identified in CFC syndrome. However, a <i>BRAF</i> p.Val600Gly pathogenic variant has been reported recently in an individual with CFC syndrome [<a class="bk_pop" href="#cfc.REF.champion.2011.468">Champion et al 2011</a>].</p></div><div id="cfc.MAP2K1_MAP2K2"><h4><i>MAP2K1</i>, <i>MAP2K2</i></h4><p><b>Gene structure.</b> MEK, like Raf, exists as a multigene family. <i>MAP2K1</i> spans approximately 104 kb. <i>MAP2K2</i> spans approximately 34 kb. Each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> contains 11 exons. For a detailed summary of gene and protein information, see <a href="/books/NBK1186/#cfc.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Missense variants in <i>MAP2K1</i> and <i>MAP2K2</i> cause CFC syndrome in approximately 25% of clinically diagnosed individuals. Pathogenic variants are heterogeneous <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> substitutions, with the majority identified in exons 2 and 3 of both <i>MAP2K1</i> and <i>MAP2K2</i>. The amino acid substitutions in MEK1 and MEK2 are similar, suggesting that the functional consequences in the two family <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> may be similar.</p><div id="cfc.T.selected_map2k1_pathogenic_variant" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>MAP2K1</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1186/table/cfc.T.selected_map2k1_pathogenic_variant/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cfc.T.selected_map2k1_pathogenic_variant_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.389A&#x0003e;G</td><td headers="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr130Cys</td><td headers="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/169790828" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002755<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/5579478" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002746<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.199G&#x0003e;A</td><td headers="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp67Asn</td></tr><tr><td headers="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.171G&#x0003e;T</td><td headers="hd_h_cfc.T.selected_map2k1_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys57Asn</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><div id="cfc.T.selected_map2k2_pathogenic_variant" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected <i>MAP2K2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1186/table/cfc.T.selected_map2k2_pathogenic_variant/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cfc.T.selected_map2k2_pathogenic_variant_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.170T&#x0003e;G</td><td headers="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe57Cys&#x000a0;<sup>1</sup></td><td headers="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/187171274" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_030662<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/13489054" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_109587<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.383C&#x0003e;A</td><td headers="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro128Gln</td></tr><tr><td headers="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.401A&#x0003e;G</td><td headers="hd_h_cfc.T.selected_map2k2_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr134Cys&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="cfc.TF.4.1"><p class="no_margin">See <a class="figpopup" href="/books/NBK1186/figure/cfc.F1/?report=objectonly" target="object" rid-figpopup="figcfcF1" rid-ob="figobcfcF1">Figure 1</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>MAP2K1</i> and <i>MAP2K2</i> encode threonine/tyrosine kinases with both <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> having the ability to activate ERK1 and ERK2. <i>MAP2K1</i> encodes the mitogen activated protein kinase 1 (MEK1). <i>MAP2K2</i> encodes MEK2. The proteins have approximately 85% amino acid identity. MEK1 and MEK2 proteins do not serve redundant purposes as determined in mouse development.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> In vitro functional studies of MEK proteins encoded by CFC syndrome-associated <i>MAP2K1</i> and <i>MAP2K2</i> pathogenic variants determine that they overstimulate ERK phosphorylation compared to <a class="def" href="/books/n/gene/glossary/def-item/wild-type/">wild-type</a> MEK; however, they are less stimulating than artificially generated constitutively active MEK pathogenic variants [<a class="bk_pop" href="#cfc.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana et al 2006</a>].</p><p><b>Cancer and benign tumors.</b> The first functional <i>MAP2K1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, p.Asp67Asn, was identified in an ovarian cancer cell line with functional studies determining that this mutated protein has increased activity as measured by an increase in ERK phosphorylation [<a class="bk_pop" href="#cfc.REF.estep.2007.e1279">Estep et al 2007</a>]. Subsequently, <i>MAP2K1</i> p.Lys57Asn pathogenic variants were identified in non-small-cell lung carcinoma [<a class="bk_pop" href="#cfc.REF.marks.2008.5524">Marks et al 2008</a>]. Since these initial publications, somatic pathogenic variants in <i>MAP2K1</i> and <i>MAP2K2</i> have been reported in various tumor types.</p></div><div id="cfc.KRAS_1"><h4><i>KRAS</i></h4><p><b>Gene structure.</b>
<i>KRAS</i> has four coding exons with intervening sequences and spans approximately 45 kb. Two alternative splice variants exist, with KRAS4b being ubiquitously expressed. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1186/#cfc.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Germline <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <i>KRAS</i> variants, which are distinct from those identified in cancer, have been identified in coding exons 1, 2, and 4b [<a class="bk_pop" href="#cfc.REF.carta.2006.129">Carta et al 2006</a>, <a class="bk_pop" href="#cfc.REF.niihori.2006.294">Niihori et al 2006</a>, <a class="bk_pop" href="#cfc.REF.schubbert.2006.331">Schubbert et al 2006</a>, <a class="bk_pop" href="#cfc.REF.zenker.2007.131">Zenker et al 2007</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The GTPase KRAS belongs to a large superfamily of small GTPases; it and its major counterparts H-Ras and N-Ras are the most extensively studied of the Ras proteins. Ras proteins regulate cell growth, proliferation, and differentiation. Ras activates several downstream cascades, some of which include the mitogen-activated protein kinase (MAPK), phosphotidylinositol 3-kinase (PI3K), RAL guanine nucleotide dissociation stimulator (RALGDS), and phospholipase C&#x003b5; (PLC&#x003b5;).</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Abnormal protein products deregulate single transduction and cause growth factor hypersensitivity of hematopoietic cells. Functional studies of NS/CFC syndrome-associated <i>KRAS</i> pathogenic variants revealed reduced intrinsic GTPase activity compared to the <a class="def" href="/books/n/gene/glossary/def-item/wild-type/">wild-type</a> protein, although not to the level of mutated K-Ras protein typically found in cancer [<a class="bk_pop" href="#cfc.REF.schubbert.2006.331">Schubbert et al 2006</a>]. Such a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> would presumably be incompatible with life.</p><p><b>Cancer and benign tumors.</b> Aberrant activation of Ras is frequently found in cancer, occurring in approximately 20% of all tumors. The vast majority of oncogenic pathogenic variants occur in hotspots in codons 12, 13, or 61. These are not the same pathogenic variants found in Noonan syndrome or CFC syndrome. Single-nucleotide variants in <i>KRAS</i> account for approximately 85% of pathogenic variants in the Ras <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> family. <i>NRAS</i> (~15% of total) and <i>HRAS</i> (~1% of total) pathogenic variants are found less frequently. Amino acid substitutions caused by pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>KRAS</i> affect guanine nucleotide binding and cause a reduction of GTP hydrolysis, resulting in a gain of function of the protein.</p></div></div></div><div id="cfc.References"><h2 id="_cfc_References_">References</h2><div id="cfc.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.abe.2012.1083">Abe Y, Aoki Y, Kuriyama S, Kawame H, Okamoto N, Kurosawa K, Ohashi H, Mizuno S, Ogata T, Kure S, Niihori T, Matsubara Y. Costello and CFC syndrome study group in Japan. Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan: findings from a nationwide epidemiological survey. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:1083–94.</span> [<a href="/pubmed/22495831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22495831</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.allanson.2011.129">Allanson JE, Anner&#x000e9;n G, Aoki Y, Armour CM, Bondeson ML, Cave H, Gripp KW, Kerr B, Nystrom AM, Sol-Church K, Verloes A, Zenker M. Cardio-facio-cutaneous syndrome: does genotype predict phenotype? <span><span class="ref-journal">Am J Med Genet C Semin Med Genet. </span>2011;<span class="ref-vol">157C</span>:129–35.</span> [<a href="/pmc/articles/PMC3086095/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3086095</span></a>] [<a href="/pubmed/21495173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21495173</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.alrahawan.2007.1481">Al-Rahawan MM, Chute DJ, Sol-Church K, Gripp KW, Stabley DL, McDaniel NL, Wilson WG, Waldron PE. Hepatoblastoma and heart transplantation in a patient with cardio-facio-cutaneous syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2007;<span class="ref-vol">143A</span>:1481–8.</span> [<a href="/pubmed/17567882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17567882</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.aoki.2005.1038">Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y. Germline mutations in HRAS proto-oncogene cause Costello syndrome. <span><span class="ref-journal">Nat Genet. </span>2005;<span class="ref-vol">37</span>:1038–40.</span> [<a href="/pubmed/16170316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16170316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.baraitser.1986.161">Baraitser M, Patton MA. A Noonan-like short stature syndrome with sparse hair. <span><span class="ref-journal">J Med Genet. </span>1986;<span class="ref-vol">23</span>:161–4.</span> [<a href="/pmc/articles/PMC1049573/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1049573</span></a>] [<a href="/pubmed/3712393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3712393</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.blumberg.1979">Blumberg B, Shapiro L, Punnett HH, Rimoin D, Kirtenmacher M. A new mental retardation syndrome with characterisitc facies, ichthyosis and abnormal hair. Paper. Chicago, IL: March of Dimes Birth Defects Conference. 1979.</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.carta.2006.129">Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb BD, Tartaglia M. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. <span><span class="ref-journal">Am J Hum Genet. </span>2006;<span class="ref-vol">79</span>:129–35.</span> [<a href="/pmc/articles/PMC1474118/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1474118</span></a>] [<a href="/pubmed/16773572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16773572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.champion.2011.468">Champion KJ, Bunag C, Estep AL, Jones JR, Bolt CH, Rogers RC, Rauen KA, Everman DB. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. <span><span class="ref-journal">Clin Genet. </span>2011;<span class="ref-vol">79</span>:468–74.</span> [<a href="/pubmed/20735442" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20735442</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.cirstea.2010.27">Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, K&#x000f6;nig R, Kratz CP, Pantaleoni F, Dentici ML, Joshi VA, Kucherlapati RS, Mazzanti L, Mundlos S, Patton MA, Silengo MC, Rossi C, Zampino G, Digilio C, Stuppia L, Seemanova E, Pennacchio LA, Gelb BD, Dallapiccola B, Wittinghofer A, Ahmadian MR, Tartaglia M, Zenker M. A restricted spectrum of NRAS mutations causes Noonan syndrome. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>:27–9.</span> [<a href="/pmc/articles/PMC3118669/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3118669</span></a>] [<a href="/pubmed/19966803" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19966803</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.estep.2007.e1279">Estep AL, Palmer C, McCormick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. <span><span class="ref-journal">PLoS One. </span>2007;<span class="ref-vol">2</span>:e1279.</span> [<a href="/pmc/articles/PMC2093994/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2093994</span></a>] [<a href="/pubmed/18060073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18060073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.makita.2007.287">Makita Y, Narumi Y, Yoshida M, Niihori T, Kure S, Fujieda K, Matsubara Y, Aoki Y. Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2007;<span class="ref-vol">29</span>:287–90.</span> [<a href="/pubmed/17483702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17483702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.marks.2008.5524">Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas RK, Rusch VW, Ladanyi M, Pao W. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. <span><span class="ref-journal">Cancer Res. </span>2008;<span class="ref-vol">68</span>:5524–8.</span> [<a href="/pmc/articles/PMC2586155/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2586155</span></a>] [<a href="/pubmed/18632602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18632602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.niihori.2006.294">Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:294–6.</span> [<a href="/pubmed/16474404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16474404</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.nowaczyk.2014.138">Nowaczyk MJ, Thompson BA, Zeesman S, Moog U, Sanchez-Lara PA, Magoulas PL, Falk RE, Hoover-Fong JE, Batista DA, Amudhavalli SM, White SM, Graham GE, Rauen KA. Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy? <span><span class="ref-journal">Clin Genet. </span>2014;<span class="ref-vol">85</span>:138–46.</span> [<a href="/pmc/articles/PMC4480871/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4480871</span></a>] [<a href="/pubmed/23379592" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23379592</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.ohtake.2011.e342">Ohtake A, Aoki Y, Saito Y, Niihori T, Shibuya A, Kure S, Matsubara Y. Non-Hodgkin lymphoma in a patient with cardiofaciocutaneous syndrome. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2011;<span class="ref-vol">33</span>:e342–6.</span> [<a href="/pubmed/20523244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20523244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.pierpont.2014.e1149">Pierpont ME, Magoulas PL, Adi S, Kavamura MI, Neri G, Noonan J, Pierpont EI, Reinker K, Roberts AE, Shankar S, Sullivan J, Wolford M, Conger B, Santa Cruz M, Rauen KA. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. <span><span class="ref-journal">Pediatrics. </span>2014;<span class="ref-vol">134</span>:e1149–62.</span> [<a href="/pmc/articles/PMC4179092/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4179092</span></a>] [<a href="/pubmed/25180280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25180280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.rauen.2006.1681">Rauen KA. Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype. <span><span class="ref-journal">Am J Med Genet A. </span>2006;<span class="ref-vol">140</span>:1681–3.</span> [<a href="/pubmed/16804887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16804887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.rauen.2011.136">Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. <span><span class="ref-journal">Am J Med Genet C Semin Med Genet. </span>2011;<span class="ref-vol">157C</span>:136–46.</span> [<a href="/pmc/articles/PMC4145816/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4145816</span></a>] [<a href="/pubmed/21495172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21495172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.rauen.2010.807">Rauen KA, Tidyman WE, Estep AL, Sampath S, Peltier HM, Bale SJ, Lacassie Y. Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations. <span><span class="ref-journal">Am J Med Genet A. </span>2010;<span class="ref-vol">152A</span>:807–14.</span> [<a href="/pmc/articles/PMC4180666/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4180666</span></a>] [<a href="/pubmed/20358587" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20358587</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.rauen.2013.355">Rauen KA. The RASopathies. <span><span class="ref-journal">Annu Rev Genomics Hum Genet. </span>2013;<span class="ref-vol">14</span>:355–69.</span> [<a href="/pmc/articles/PMC4115674/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4115674</span></a>] [<a href="/pubmed/23875798" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23875798</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.reynolds.1986.413">Reynolds JF, Neri G, Herrmann JP, Blumberg B, Coldwell JG, Miles PV, Opitz JM. New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement--the CFC syndrome. <span><span class="ref-journal">Am J Med Genet. </span>1986;<span class="ref-vol">25</span>:413–27.</span> [<a href="/pubmed/3789005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3789005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.roberts.2006.833">Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, Young T, Neri G. The cardiofaciocutaneous syndrome. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:833–42.</span> [<a href="/pmc/articles/PMC2563180/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563180</span></a>] [<a href="/pubmed/16825433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16825433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. <span><span class="ref-journal">Science. </span>2006;<span class="ref-vol">311</span>:1287–90.</span> [<a href="/pubmed/16439621" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16439621</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.sarkozy.2009.695">Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F, Petrangeli V, Dentici ML, Mancini GM, Selicorni A, Rossi C, Mazzanti L, Marino B, Ferrero GB, Silengo MC, Memo L, Stanzial F, Faravelli F, Stuppia L, Puxeddu E, Gelb BD, Dallapiccola B, Tartaglia M. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:695–702.</span> [<a href="/pmc/articles/PMC4028130/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4028130</span></a>] [<a href="/pubmed/19206169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19206169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.schubbert.2006.331">Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP. Germline KRAS mutations cause Noonan syndrome. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:331–6.</span> [<a href="/pubmed/16474405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16474405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.siegel.2011.521">Siegel DH, McKenzie J, Freiden I, Rauen KA. Dermatological findings in 61 mutation-positive individuals with cardio-facio-cutaneous syndrome. <span><span class="ref-journal">Br J Dermatol. </span>2011;<span class="ref-vol">164</span>:521–9.</span> [<a href="/pmc/articles/PMC4063552/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4063552</span></a>] [<a href="/pubmed/21062266" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21062266</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.solchurch.2009.315">Sol-Church K, Stabley DL, Demmer LA, Agbulos A, Lin AE, Smoot L, Nicholson L, Gripp KW. Male-to-male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism. <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:315–21.</span> [<a href="/pmc/articles/PMC2653086/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2653086</span></a>] [<a href="/pubmed/19206176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19206176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.stark.2012.590">Stark Z, Gillessen-Kaesbach G, Ryan MM, Cirstea IC, Gremer L, Ahmadian MR, Savarirayan R, Zenker M. Two novel germline KRAS mutations: expanding the molecular and clinical phenotype. <span><span class="ref-journal">Clin Genet. </span>2012;<span class="ref-vol">81</span>:590–4.</span> [<a href="/pubmed/21797849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21797849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.tartaglia.2001.465">Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:465–8.</span> [<a href="/pubmed/11704759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11704759</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.tartaglia.2007.75">Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:75–9.</span> [<a href="/pubmed/17143282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17143282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.tidyman.2009a.230">Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. <span><span class="ref-journal">Curr Opin Genet Dev. </span>2009a;<span class="ref-vol">19</span>:230–6.</span> [<a href="/pmc/articles/PMC2743116/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2743116</span></a>] [<a href="/pubmed/19467855" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19467855</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.wellbrock.2004.875">Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. <span><span class="ref-journal">Nat Rev Mol Cell Biol. </span>2004;<span class="ref-vol">5</span>:875–85.</span> [<a href="/pubmed/15520807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15520807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.yoon.2007.894">Yoon G, Rosenberg J, Blaser S, Rauen KA. Neurological complications of cardio-facio-cutaneous syndrome. <span><span class="ref-journal">Dev Med Child Neurol. </span>2007;<span class="ref-vol">49</span>:894–9.</span> [<a href="/pubmed/18039235" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18039235</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.yu.2011.1593">Yu S, Graf WD. BRAF gene deletion broadens the clinical spectrum neuro-cardio-facial-cutaneous syndromes. <span><span class="ref-journal">J Child Neurol. </span>2011;<span class="ref-vol">26</span>:1593–6.</span> [<a href="/pubmed/21862832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21862832</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cfc.REF.zenker.2007.131">Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante AS, Raskin S, Schnabel D, Wehner LE, Kratz CP, Horn D, Kutsche K. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. <span><span class="ref-journal">J Med Genet. </span>2007;<span class="ref-vol">44</span>:131–5.</span> [<a href="/pmc/articles/PMC2598066/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2598066</span></a>] [<a href="/pubmed/17056636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17056636</span></a>]</div></li></ul></div></div><div id="cfc.Chapter_Notes"><h2 id="_cfc_Chapter_Notes_">Chapter Notes</h2><div id="cfc.Author_Notes"><h3>Author Notes</h3><p>Dr Rauen serves on the Medical Advisory Board for CFC International, Inc and is co-director and member of the Professional Advisory Board for The Costello Syndrome Family Network. She also is a member of the RASopathies Network Scientific Advisory Board and the Global Genes Advisory Board.</p><p>Dr Rauen is the Director of the <a href="http://www.ucdmc.ucdavis.edu/mindinstitute/clinic/genomic-medicine/RASclinic.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UC Davis NF/Ras Pathway Genetics Clinic</a>.</p></div><div id="cfc.Acknowledgments"><h3>Acknowledgments</h3><p>Special thanks to Brenda Conger, President, and Molly Santa Cruz, Vice President, of CFC International and all the families of CFC International and the Costello syndrome Family Network for their ongoing support of research in genetic medicine. This work was supported in part by NIH grant HD048502.</p></div><div id="cfc.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>3 March 2016 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 September 2012 (cd) Revision: multigene panels for Noonan / Costello / LEOPARD / cardiofaciocutaneous syndrome(s) (RAS/MAPK pathway) available clinically</div></li><li class="half_rhythm"><div>23 December 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 January 2007 (me) Review posted live</div></li><li class="half_rhythm"><div>14 September 2006 (kar) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1186</span><span class="label">PMID: <a href="/pubmed/20301365" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301365</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ca5a-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/carney/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1186&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1186/?report=reader">PubReader</a></li><li><a href="/books/NBK1186/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1186" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1186" style="display:none" title="Cite this Page"><div class="bk_tt">Rauen KA. Cardiofaciocutaneous Syndrome. 2007 Jan 18 [Updated 2016 Mar 3]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1186/pdf/Bookshelf_NBK1186.pdf">PDF version of this page</a> (554K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#cfc.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#cfc.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#cfc.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#cfc.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#cfc.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#cfc.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#cfc.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#cfc.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#cfc.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#cfc.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#cfc.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3845[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KRAS</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=673[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BRAF</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5605[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MAP2K2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5604[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MAP2K1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1481788" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1481788" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1481788" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1481788" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301303" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Noonan Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Noonan Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Allanson JE, Roberts AE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301680" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Costello Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Costello Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gripp KW, Rauen KA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21062266" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome.</a><span class="source">[Br J Dermatol. 2011]</span><div class="brieflinkpop offscreen_noflow">Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Siegel DH, McKenzie J, Frieden IJ, Rauen KA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Br J Dermatol. 2011 Mar; 164(3):521-9. Epub 2011 Jan 28.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301510" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Marfan Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Marfan Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dietz H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301557" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Noonan Syndrome with Multiple Lentigines</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Noonan Syndrome with Multiple Lentigines<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gelb BD, Tartaglia M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301365" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301365" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040dd475f66d18aa9f3c44">Cardiofaciocutaneous Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Cardiofaciocutaneous Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:33:08-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8ABD22E03F5AA100000000090702E4&amp;ncbi_session=CE8ABD22E040DD41_2311SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1186%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1186&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1186/&amp;ncbi_pagename=Cardiofaciocutaneous Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8ABD22E040DD41_2311SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>